Sleep Month in Review: December 2024
HCPLive
JANUARY 8, 2025
This Month in Review captures 7 sleep medicine news, including FDA updates, from December 2024.
Wed.Jan 08, 2025
97 
Chlorthalidone vs. Hydrochlorothiazide for Hypertension: Renal Outcomes
NEJM Journal Watch - Cardiology
JANUARY 8, 2025
In a secondary analysis from a randomized trial, no important differences were noted.
Varipulse Heart Device Procedures Paused After Safety Events
Med Page Today
JANUARY 8, 2025
(MedPage Today) -- Just months after FDA approval, Johnson & Johnson paused the rollout of its Varipulse pulsed field ablation (PFA) platform in the U.S. due to safety reasons. In a U.S. external evaluation cohort, four reported neurovascular.
Exposure to aircraft noise linked to worse heart function
Science Daily - Heart Disease
JANUARY 8, 2025
People who live close to airports and are exposed to high aircraft noise levels could be at greater risk of poor heart function, increasing the likelihood of heart attacks, life-threatening heart rhythms and strokes, according to a new study.
Development and validation of a prediction model for coronary heart disease risk in depressed patients aged 20 years and older using machine learning algorithms
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
BackgroundDepression is being increasingly acknowledged as an important risk factor contributing to coronary heart disease (CHD). Currently, there is no predictive model specifically designed to evaluate the risk of coronary heart disease among individuals with depression. We aim to develop a machine learning (ML) model that will analyze risk factors and forecast the probability of coronary heart disease in individuals suffering from depression.MethodsThis research employed data from the Nationa
Inside the expansion plans of Broward Health's 1st cardiology chief
Becker's Hospital Review - Cardiology
JANUARY 8, 2025
Jose Baez-Escudero, MD, in November stepped into his role as the first systemwide chief of cardiology at Fort Lauderdale, Fla.-based Broward Health, where he also now serves as chief of cardiac electrophysiology.
C-Reactive Protein Effective as Biomarker for HS Treated with Adalimumab
HCPLive
JANUARY 8, 2025
Patients in this post-hoc analysis with elevated CRP were found to have a higher BMI and more severe hidradenitis suppurativa.
Sign up to get articles personalized to your interests!
Cardiovascular Update brings together the best content for cardiovascular medicine professionals from the widest variety of industry thought leaders.
More Trending
Biosimilars Month in Review: December 2024
HCPLive
JANUARY 8, 2025
The biosimilars month in review highlights a newly approved ustekinumab biosimilar and a look into the field in 2024.
The efficacy and safety of indobufen in patients with ischemic cardiovascular or cerebrovascular diseases: systematic review and meta-analysis
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
ObjectiveThis meta-analysis aims to evaluate the safety and efficacy of indobufen in the treatment of cardiovascular diseases, cerebrovascular diseases, and thromboembolic disorders. The primary focus is on the incidence of major adverse cardiovascular events (MACE), thrombosis, bleeding events, and adverse reactions. The results are intended to provide a reference for the clinical application of indobufen and suggest directions for further large-scale, multi-center, prospective studies.MethodsT
Alcohol-Associated Liver Disease, MASLD Drive Growing Liver Cancer Burden in the US
HCPLive
JANUARY 8, 2025
From 2000 to 2021, primary liver cancer incidences and deaths in the US increased by more than 100%, driven by rapid growth in ALD and MASLD.
DEPDC1B, CDCA2, APOBEC3B, and TYMS are potential hub genes and therapeutic targets for diagnosing dialysis patients with heart failure
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
IntroductionHeart failure (HF) has a very high prevalence in patients with maintenance hemodialysis (MHD). However, there is still a lack of effective and reliable HF diagnostic markers and therapeutic targets for patients with MHD.MethodsIn this study, we analyzed transcriptome profiles of 30 patients with MHD by high-throughput sequencing. Firstly, the differential genes between HF group and control group of patients with MHD were screened.
FDA Grants Orphan Drug Designation to CNP-104 for Primary Biliary Cholangitis
HCPLive
JANUARY 8, 2025
The designation follows positive topline data from the phase 2a trial of CNP-104 in PBC, which were presented at AASLDs The Liver Meeting
The Extravascular Implantable Cardioverter-Defibrillator: A Promising Novel Device
American College of Cardiology
JANUARY 8, 2025
Transvenous implantable cardioverter-defibrillators (ICDs) are the reference standard for preventing sudden cardiac death (SCD) but have risks associated with intravascular lead placement.
Global Atopic Dermatitis Among Children Projected to Rise Over 50 Years
HCPLive
JANUARY 8, 2025
This analysis using worldwide data from GBD 2021 indicates that the global burden of eczema in children has gradually risen and has been projected to continue increasing.
Impact of high hemoglobin levels on carotid artery intima–media thickness and its predictive value for hypertension in high-altitude areas: a real-world study
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
Background and purposeThe hemoglobin levels in the peripheral blood of individuals living at high altitudes are significantly higher than normal levels. These levels are closely associated with atherosclerosis and cardiovascular events. This study aimed to investigate the correlation between hemoglobin levels in the peripheral blood and hypertension in high-altitude regions, providing a basis for preventing and treating primary hypertension in these regions.Materials and methodsFrom May 2020 to
LB-102 Shows Promise in Reducing Acute Schizophrenia Symptoms: New Phase 2 Data
HCPLive
JANUARY 8, 2025
Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.
Mineralys Therapeutics Announces Phase 2 Clinical Trial of Lorundrostat
DAIC
JANUARY 8, 2025
tim.hodson Wed, 01/08/2025 - 14:11 Jan. 8, 2025 Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases, hasannounced that the U.S. Food and Drug Administration (FDA) has cleared the companys Investigational New Drug (IND) Application for a Phase 2 clinical trial to evaluate the effect of lorundrostat in the treatment of subjects with moderate-to-severe obstructive sleep apne
Pediatric Lipid Treatment Recommendations
HCPLive
JANUARY 8, 2025
Panelists discuss how statin therapy can be initiated in children with familial hypercholesterolemia as early as 8 to 10 years old, following careful evaluation and lifestyle interventions.
Key Updates in the 2025 American Diabetes Association (ADA) Diabetes GuidelinesÂ
Cardiometabolic Health Congress
JANUARY 8, 2025
Last month, the 2025 American Diabetes Association (ADA) guidelines were introduced, providing updates for diagnosing and managing diabetes and prediabetes. These new guidelines offer actionable, evidence-based recommendations to improve care delivery. 1. ADA Updates: Continuous Glucose Monitoring (CGM) for Type 2 Diabetes on Glucose-Lowering Agents The ADA now recommends considering CGM for adults with type 2 diabetes who are using glucose-lowering agents other than insulin.
APOC3 Inhibitors
HCPLive
JANUARY 8, 2025
Panelists discuss important novel therapies emerging for familial chylomicronemia syndrome (FCS), focusing on APOC3 inhibitors, including small interfering RNA (siRNA) and antisense oligonucleotides (ASO), and their potential to address the underlying lipid metabolism dysfunction in patients with FCS.
American College of Cardiology to honor 21 industry leaders
Becker's Hospital Review - Cardiology
JANUARY 8, 2025
"Discover the 21 industry leaders being honored by the American College of Cardiology for their contributions to global cardiovascular care and outcomes.
Navigating Lifestyle and Pharmacotherapy Interventions in Dyslipidemia Management
HCPLive
JANUARY 8, 2025
Panelists discuss how lifestyle interventions, including diet, physical activity, and smoking cessation, complement pharmacotherapy in the management of dyslipidemia, and explore unmet needs in cardiovascular risk reduction, highlighting the role of emerging therapies such as bempedoic acid, inclisiran, and gene editing technologies.
Clinically relevant haemolysis after transcatheter aortic valve implantation with new-generation balloon-expandable valve
Open Heart
JANUARY 8, 2025
Background Valve-related haemolysis is a known complication following prosthetic valve surgery. Haemolysis after transcatheter aortic valve implantation (TAVI) has been reported in some studies, all of which were non-critical. Data related to haemolysis associated with new-generation balloon-expandable valve (BEV) are scarce. Methods Among 441 patients who underwent TAVI between April 2023 and June 2024, 282 patients treated with new-generation BEV were analysed.
Mortality and Comorbidities with COPD
HCPLive
JANUARY 8, 2025
Panelists discuss current statistics indicating that COPD is one of the top three leading causes of death worldwide, with high morbidity and mortality rates, particularly in individuals over 40 years of age, and a growing global burden due to risk factors like smoking and air pollution.
Exposure to specific polyfluoroalkyl chemicals is associated with cardiovascular disease in US adults: a population-based study
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
BackgroundPolyfluoroalkyl chemicals (PFCs) present potential health risks due to their persistence and bioaccumulation. However, there is currently insufficient evidence regarding their impact on cardiovascular disease (CVD). Consequently, it is imperative to investigate the correlation between PFCs and CVD.MethodsThe data was collected from National Health and Nutrition Examination Survey in 20052012.
Young Women Face Worse Long-Term Alcohol-Associated Hepatitis Outcomes Than Men
HCPLive
JANUARY 8, 2025
Study findings highlight increasing rates of AH among adolescents and younger adults, with women facing worse long-term liver-related outcomes.
Levosimendan for sepsis-induced myocardial dysfunction: friend or foe?
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
Sepsis-induced myocardial dysfunction (SIMD) involves reversible myocardial dysfunction. The use of inotropes can restore adequate cardiac output and tissue perfusion, but conventional inotropes, such as dobutamine and adrenaline, have limited efficacy in such situations. Levosimendan is a novel inotrope that acts in a catecholamine-independent manner.
Polypill Therapy Cost-Effective for CVD Risk in Underserved Populations
HCPLive
JANUARY 8, 2025
An economic analysis highlights a cardiovascular polypill's potential to lower healthcare costs and address income-based health disparities.
Heart Failure with Preserved Ejection Fraction
The New England Journal of Medicine
JANUARY 8, 2025
Heart failure with preserved ejection fraction is noted for symptoms of heart failure, LVEF of at least 50%, and cardiac or structural abnormalities. Treatment includes diuretics and SGLT2 inhibitors.
Long-Acting Injectables Effectively Manage Bipolar Mania in Adolescents
HCPLive
JANUARY 8, 2025
A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.
Evolution of de Winter syndrome to Wellens syndrome: a case report and literature review
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
Both de Winter syndrome and Wellens syndrome mainly indicate severe stenosis in the proximal segment of the anterior descending coronary artery. However, as research deepens, the accuracy and specificity of diagnosing proximal left anterior descending coronary artery (LAD) culprit lesions separately by de Winter syndrome or Wellens syndrome are challenged.
Patient Case No. 2
HCPLive
JANUARY 8, 2025
Panelists discuss how chronic kidney disease (CKD) and uncontrolled hypertension create a damaging cycle, in which hypertension accelerates kidney damage while declining kidney function makes blood pressure harder to control.
Case Report: Painful left bundle branch block syndrome complicated with vasovagal syncope
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
BackgroundPainful left bundle branch block (LBBB) syndrome is an uncommon disease that is defined as intermittent episodes of angina associated with simultaneous LBBB changes on an electrocardiogram (ECG) with the absence of flow-limiting coronary artery disease or ischemia on functional testing. Vasovagal syncope (VVS) is the most common cause of syncope and can be provoked by sublingual nitroglycerin (NTG).
International Lipid Expert Panel Recommendations and RACING Trial
HCPLive
JANUARY 8, 2025
Panelists discuss how the International Lipid Expert Panel advocates for combination therapy as initial treatment in patients with elevated LDL-C and very high cardiovascular risk rather than sequential monotherapy.
The type of exercise most beneficial for quality of life in people with atrial fibrillation: a network meta-analysis
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
IntroductionAtrial fibrillation (AF) significantly detracts from health-related quality of life (HRQoL). Despite the promotion of exercise interventions for managing AF, the effectiveness of different exercise modalities remains to be clearly defined. This systematic review and network meta-analysis aims to evaluate the comparative effectiveness of various modes of exercise interventions on HRQoL in AF patients.MethodsA random-effect network meta-analysis was performed.
Nephrology Month in Review: December 2024
HCPLive
JANUARY 8, 2025
The month in review features coverage of renal pipeline updates, a new nephrology podcast episode, and recent research in IgAN and FSGS.
Evolving perspectives on aortic stenosis: the increasing importance of evaluating the right ventricle before aortic valve intervention
Frontiers in Cardiovascular Medicine
JANUARY 8, 2025
Aortic stenosis (AS) was historically considered a disease of the left side of the heart, with the main pathophysiological impact being predominantly on the left ventricle (LV). However, progressive pressure overload in AS can initiate a cascade of extra-valvular myocardial remodeling that could also precipitate maladaptive alterations in the structure and function of the right ventricle (RV).
Let's personalize your content